|Bid||0.00 x 1800|
|Ask||0.00 x 1400|
|Day's Range||16.33 - 16.78|
|52 Week Range||12.89 - 21.20|
|Beta (3Y Monthly)||1.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.88|
Ironwood Pharmaceuticals Inc’s (NASDAQ:IRWD): Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The US$2.6b market-cap company’s loss lessens since it Read More...
NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding IRWD is favorable, with net inflows of $7.58 billion.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotechnology company, today announced the presentation of clinical data for IW-3718 and linaclotide from the company and its collaborators during the American College of Gastroenterology 2018 Annual Scientific Meeting in Philadelphia, PA, October 5 through October 10, 2018. IW-3718 is being evaluated in Phase III clinical trials for the treatment of persistent gastroesophageal reflux disease (GERD). Persistent GERD is a condition affecting an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton pump inhibitors, the current standard of care.
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.
NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Wall Street closed up on Thursday as tech shares rallied and trade tensions eased on the hopes of a fresh round of trade talks, that could potentially take ...
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for praliciguat (IW-1973) for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). Praliciguat is an investigational, orally administered soluble guanylate cyclase (sGC) stimulator currently in Phase II clinical trials.
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcasts will be available on Ironwood’s website for 14 days following the conference.
Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc (Nasdaq: IRWD , “Ironwood”) today announced that approval has been obtained in Japan for the guanylate cyclase-C receptor agonist “Linzess® Tablets 0.25 mg (generic name: linaclotide)” for the additional indication of chronic constipation (other than constipation associated with organic disorders1) (“chronic constipation”). Linzess® Tablets 0.25 mg were licensed from Ironwood and have been developed and commercialized in Japan by Astellas.
Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.
Tesaro (TSRO) is a commercial-stage biopharmaceutical company primarily focused on developing treatments for solid tumors by using small molecules and immune-oncology antibodies both as monotherapies and in combinations. Tesaro’s key product, Zejula, has been approved in the United States as well as the European Union as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tesaro commercialized Zejula in the United States in April 2017 and in Europe in December 2017.
Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter compared to $387 million in the second quarter of 2017, which reflected ~14% YoY (year-over-year) growth.
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.
NEW YORK, Aug. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Omnicom ...
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.
Ironwood (IRWD) delivered earnings and revenue surprises of -47.37% and -9.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 32 cents per share. Losses, adjusted for amortization costs and non-recurring costs, came to 28 cents per share. The results fell short ...